A sustained-release composition of tranexamic acid and a preparation process and application thereof

By combining fluidized bed granulation technology with sustained-release materials, the release rate of tranexamic acid is controlled, solving the problems of excessively rapid release and short effective duration, thus achieving steady-state blood drug concentration and reducing gastrointestinal irritation.

CN122124024APending Publication Date: 2026-06-02南方医科大学第五附属医院
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
南方医科大学第五附属医院
Filing Date
2026-04-13
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing tranexamic acid sustained-release solid dosage forms have problems such as excessively rapid release rate and short effective duration, leading to frequent gastrointestinal adverse reactions and multiple administration times.

Method used

A sustained-release composition of tranexamic acid was prepared by using the synergistic effect of sustained-release materials and polyvinyl alcohol through fluidized bed granulation. By combining materials such as hydroxypropyl cellulose and ethyl cellulose, the release rate of the drug was controlled to form a steady-state blood drug concentration.

Benefits of technology

This achieves zero-order or first-order drug release, prolongs the drug's duration of action in the body, reduces gastrointestinal irritation, and improves bioavailability and treatment safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention belongs to the field of biopharmaceutical technology and discloses a tranexamic acid sustained-release composition, its preparation process, and its application. By weight, the composition comprises 100-120 parts tranexamic acid, 14-18 parts sustained-release material, 5-8 parts magnesium stearate, 2-5 parts colloidal silica, and 3-5 parts polyvinyl alcohol. The sustained-release material is selected from a combination of hydroxypropyl cellulose and ethyl cellulose, or a combination of hydroxypropyl methyl cellulose and microcrystalline cellulose, or a combination of sodium carboxymethyl cellulose and hydrogenated vegetable oil. This invention utilizes the synergistic effect of the sustained-release material and the synergistic effect between the sustained-release material and polyvinyl alcohol to maintain zero-order or first-order release of the drug, achieving a steady-state blood drug concentration and prolonging the duration of action, thereby achieving a good sustained-release effect.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Tranexamic acid formulations with reduced adverse effects

    US20090214644A1

  • Tranexamic Acid Formulations

    US20100143468A1

  • Modified Release Tranexamic Acid Formulation

    US20120135079A1